Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR33346953

—

7124a9ff-0635-5373-b1ce-f738975e5790

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
  • TNFA_SIGNALING_VIA_NFKB+0.630
  • ANGIOGENESIS+0.580
  • INFLAMMATORY_RESPONSE+0.530
  • UV_RESPONSE_DN+0.500
  • IL6_JAK_STAT3_SIGNALING+0.490
  • IL2_STAT5_SIGNALING+0.470
  • KRAS_SIGNALING_UP+0.470
  • MYOGENESIS+0.460
  • COAGULATION+0.430

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.290
  • OXIDATIVE_PHOSPHORYLATION-0.250
  • MYC_TARGETS_V1-0.080
  • DNA_REPAIR-0.070
  • MYC_TARGETS_V2-0.050
  • NOTCH_SIGNALING-0.050
  • GLYCOLYSIS-0.030
  • BILE_ACID_METABOLISM-0.020
  • FATTY_ACID_METABOLISM+0.000
  • PEROXISOME+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG918
mng-umap@100
——0.894
2MBCProject_0022_T1_RNA
breast-umap@18
—D0.879
3TCGA-22-4609-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.878
4ULC1700T_S19
lung-landscapes@6
—cohortMD20.869
5MNG281
mng-umap@100
——0.866
6MDT-AP-2040
medullo-epn-umap@date-based
MedMedulloblastoma0.866
7TCGA-43-6647-01A-11R-1820-07
lung-landscapes@6
—cohortSQ10.861
8SRR26320076
bladder-landscape@3
——0.860
9MNG824
mng-umap@100
——0.858
10TCGA-60-2707-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.856

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 40 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.630Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.630Inavolisib— uncovered
ANGIOGENESIS0.580Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.530Idelalisib— uncovered
UV_RESPONSE_DN0.500Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.490Inavolisib— uncovered
IL2_STAT5_SIGNALING0.470Idelalisib— uncovered
KRAS_SIGNALING_UP0.470Inavolisib— uncovered
MYOGENESIS0.460Inavolisib— uncovered
COAGULATION0.430Binimetinib— uncovered
ALLOGRAFT_REJECTION0.420Idelalisib— uncovered
APOPTOSIS0.410Idelalisib— uncovered
ANDROGEN_RESPONSE0.400Inavolisib— uncovered
APICAL_JUNCTION0.400Inavolisib— uncovered
HEDGEHOG_SIGNALING0.400Inavolisib— uncovered
COMPLEMENT0.390Inavolisib— uncovered
TGF_BETA_SIGNALING0.360Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.250Idelalisib— uncovered